PL2935313T3 - Szczepionki przeciwko wirusowi zapalenia wątroby typu b - Google Patents

Szczepionki przeciwko wirusowi zapalenia wątroby typu b

Info

Publication number
PL2935313T3
PL2935313T3 PL13814593T PL13814593T PL2935313T3 PL 2935313 T3 PL2935313 T3 PL 2935313T3 PL 13814593 T PL13814593 T PL 13814593T PL 13814593 T PL13814593 T PL 13814593T PL 2935313 T3 PL2935313 T3 PL 2935313T3
Authority
PL
Poland
Prior art keywords
virus
vaccines against
against hepatitis
hepatitis
vaccines
Prior art date
Application number
PL13814593T
Other languages
English (en)
Inventor
Bertrand Victor Gilbert GEORGES
Carlton Bradley BROWN
Original Assignee
Altimmune Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune Uk Limited filed Critical Altimmune Uk Limited
Publication of PL2935313T3 publication Critical patent/PL2935313T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13814593T 2012-12-24 2013-12-20 Szczepionki przeciwko wirusowi zapalenia wątroby typu b PL2935313T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
EP13814593.3A EP2935313B1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
PL2935313T3 true PL2935313T3 (pl) 2022-05-02

Family

ID=47682590

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13814593T PL2935313T3 (pl) 2012-12-24 2013-12-20 Szczepionki przeciwko wirusowi zapalenia wątroby typu b

Country Status (12)

Country Link
US (3) US10300132B2 (pl)
EP (2) EP3995146A1 (pl)
JP (3) JP6811014B2 (pl)
KR (3) KR102625645B1 (pl)
CN (2) CN114028553A (pl)
CA (1) CA2895459A1 (pl)
DK (1) DK2935313T3 (pl)
EA (1) EA201591213A1 (pl)
ES (1) ES2906110T3 (pl)
GB (1) GB201223386D0 (pl)
PL (1) PL2935313T3 (pl)
WO (1) WO2014102540A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
PT3463436T (pt) 2016-06-02 2023-12-28 Ultimovacs As Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
JP2021520414A (ja) * 2018-04-04 2021-08-19 アルティミューン インコーポレーティッド T細胞を誘発するワクチン組成物の組合せ及びその使用
CN113939527B (zh) * 2019-01-11 2025-10-28 新加坡科技研究局 Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途
CA3141238A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
BR112022003474A2 (pt) * 2019-08-29 2022-05-24 Triad Nat Security Llc Vacinas do vírus da hepatite b
EP4069271A1 (en) 2019-12-07 2022-10-12 ISA Pharmaceuticals B.V. Treatment of diseases related to hepatitis b virus
CN115335076B (zh) * 2020-01-09 2025-10-28 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法
CA3184495A1 (en) * 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Anti-hbv antibodies and methods of use
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
WO2026093412A2 (en) * 2024-10-29 2026-05-07 Nec Oncoimmunity As Hbv vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
JP3566284B2 (ja) 1991-08-26 2004-09-15 ザ スクリップス リサーチ インスティテュート B型肝炎ウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド類
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
CN1454082A (zh) 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Also Published As

Publication number Publication date
EA201591213A1 (ru) 2016-02-29
KR102625645B1 (ko) 2024-01-15
DK2935313T3 (da) 2022-02-28
JP2019034946A (ja) 2019-03-07
US11382969B2 (en) 2022-07-12
EP3995146A1 (en) 2022-05-11
CN114028553A (zh) 2022-02-11
JP6811014B2 (ja) 2021-01-13
JP7187237B2 (ja) 2022-12-12
US11918645B2 (en) 2024-03-05
GB201223386D0 (en) 2013-02-06
KR20230021771A (ko) 2023-02-14
EP2935313A1 (en) 2015-10-28
US10300132B2 (en) 2019-05-28
CA2895459A1 (en) 2014-07-03
CN104903343A (zh) 2015-09-09
KR102497063B1 (ko) 2023-02-06
JP7235785B2 (ja) 2023-03-08
ES2906110T3 (es) 2022-04-13
WO2014102540A1 (en) 2014-07-03
KR20150098676A (ko) 2015-08-28
US20230090379A1 (en) 2023-03-23
JP2021098711A (ja) 2021-07-01
US20160106830A1 (en) 2016-04-21
JP2016505589A (ja) 2016-02-25
KR20220019846A (ko) 2022-02-17
EP2935313B1 (en) 2021-11-24
KR102358621B1 (ko) 2022-02-03
US20200016263A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL261204A (en) Influenza virus vaccines and their use
ZA201404797B (en) Influenza virus vaccines and uses thereof
SG11201400743VA (en) Influenza virus vaccines and uses thereof
IL235890A0 (en) vaccine
EP2806891A4 (en) VACCINES BASED ON PARAINFLUENZA VIRUS 5
ZA201404516B (en) Vaccines against hpv
ZA201509229B (en) Influenza virus vaccines and uses thereof
IL229307A0 (en) Inactivated dengue virus vaccine
DK2935313T3 (da) Vacciner mod hepatitis B-virus
ZA201503458B (en) Hepatitis c virus inhibitors
ZA201503036B (en) Chimeric vaccine antigens against hepatitis c virus
PL2852614T3 (pl) Szczepionka oparta na składniku dopełniacza - C5A
PL2958935T3 (pl) Szczepionka
SI2850075T1 (sl) Piperazin-piperidinske spojine kot inhibitorji virusa hepatitisa C
GB201301119D0 (en) Viral vaccines
GB201215184D0 (en) Therapeutic virus
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
SG11201507455WA (en) Hepatitis b virus vaccines
DK2846829T3 (en) Vaccine combinations
SG11201505170WA (en) Dengue virus vaccine composition
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine
AU2013905065A0 (en) Viral vaccine